Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data

Rheumatology

Volumn 42, Issue 11, 2003, Pages 1354-1364

  Layton, Deborah ^a,b   Hughes, Kerry ^a   Harris, Scott ^a,c   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Adverse events; Celecoxib; COX 2 selective inhibitors; Drug safety; Meloxicam

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; WARFARIN;

ADULT; AGE; AGED; ARTICLE; BLEEDING; BRAIN EMBOLISM; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; GASTROINTESTINAL TOXICITY; GENDER; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATIC DISEASE; RISK FACTOR; STATISTICAL MODEL; THROMBOEMBOLISM; UNITED KINGDOM; VEIN THROMBOSIS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CEREBROVASCULAR DISORDERS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CYCLOOXYGENASE INHIBITORS; ENGLAND; FAMILY PRACTICE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOARTHRITIS; PERIPHERAL VASCULAR DISEASES; PYRAZOLES; RISK FACTORS; SULFONAMIDES; SURVIVAL ANALYSIS; THIAZINES; THIAZOLES; THROMBOEMBOLISM;

EID: 0242472759     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg401     Document Type: Article

References (52)

1. Jackson LM, Hawkey CJ. COX-2 selective nonsteroidal anti -inflammatory drugs: do they really offer any advantages? Drugs 2000;59:1207-16.
2. Hawkey C, Laine L, Simon T et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000;43:370-7.
3. Laine L, Harper S, Simon T et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999; 117:776-83.
4. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8. [Plus 2 pages following 1528.]
5. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med 1999;107:48S-54S.
6. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 2000;284:1247-55.
7. FitzGerald GA, Cheng Y, Austin S. COX-2 inhibitors and the cardiovascular system. Clin Exp Rheumatol 2001;19 (6 Suppl. 25):S31-6.
8. Food and Drug Administration advisory committee. Cardiovascular safety review of rofecoxib. 2001. http:/www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf.
9. Seibert K, Masferrer JL, Fu JY, Honda A, Raz A, Needleman P. The biochemical and pharmacological manipulation of cellular cyclooxygenase (COX) activity. Adv Prostaglandin Thromboxane Leukot Res 1991;21A:45-51.
10. Brooks P, Emery P, Evans JF et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 1999;38:779-88.
11. Lipsky PE, Abramson SB, Breedveld FC et al. Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. J Rheumatol 2000;27:1338-40.
12. Catella-Lawson F. Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. Neurology 2001;57 (5 Suppl. 2):S5-7.
13. Kam PC, See AU. Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 2000;55:442-9.
14. Brochier ML. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Eur Heart J 19931-14: 951-7.
15. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118-23.
16. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000;11:382-7.
17. Freston JW. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. Am J Med 1999;107:78S-88S.
18. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272-7.
19. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000;40:124-32.
20. Linder JD, Monkemuller KE, Davis JV, Wilcox CM. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia. South Med J 2000;93:930-2.
21. Crofford LJ, Oates JC, McCune WJ et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis Rheum 2000;43:1891-6.
22. Haase KK, Rojas-Fernandez CH, Lane L, Frank DA. Potential interaction between celecoxib and warfarin. Ann Pharmacother 2000;34:666-7.
23. Anon. Celecoxib: early Australian reporting experience. Aust Adv Drug Reactions Bull 2000;19:6-7.
24. Noble S, Balfour JA. Meloxicam. Drugs 1996;51:424-30.
25. Panara MR, Renda G, Sciulli MG et al. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther 1999;290:276-80.
26. Layton D, Heeley E, Hughes K, Shakir SA. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data. Rheumatology 2003;42:622-31.
27. Kaplan-Machlis B, Klostermeyer BS. The cyclooxygenase-2 inhibitors: safety and effectiveness. Ann Pharmacother 1999;33:979-88.
28. Wojtulewski JA, Schattenkirchner M, Barcelo P et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5mg daily and naproxen 750mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996;35(Suppl. 1):22-8.
29. Lemmel EM, Bolten W, Burgos-Vargas R et al. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J Rheumatol 1997;24:282-90.
30. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996;35(Suppl. 1):68-77.
31. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc 2001-286:954-9.
32. Konstam MA, Weir Mk, Reicin A et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-8.
33. Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arellano FM. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 2001; 23:1478-91.
34. Mann RD. Prescription-event monitoring recent progress and future horizons. Br J Clin Pharmacol 1998;46: 195-201.
35. Shakir SA. PEM in the UK. In: Mann RD, Andrews E, eds. Pharmacovigilance, Chichester, UK: John Wiley & Sons, 2002:333-44.
36. Legemaate J. The CIOMS guidelines for biomedical research involving human subjects. Eur J Health Law 1994;1:161-5.
37. Royal College of Physicians of London. Guidelines on the practice of Ethical Committees in Medical Research involving Human Subjects. 1996.
38. Multi-Centre Research Ethics Committees Guidance Notes. Examples of enquiries and surveys in the public interest where no reference to a Research Ethics Committee is necessary. Appendix C, 2000. http://www.corec.org.uk/wordDocs/Guidenotes.doc
39. Martin RM, Biswas P, Mann RD. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br J Clin Pharmacol 2000;50:35-42.
40. Layton D, Wilton LW, Shakir SA. Celecoxib. PEM report No.74. 2002.
41. Mann RD, Rawlins MD, Fletcher P. Age and the spontaneous reporting of adverse reactions in the United Kingdom. Pharmacoepidemiol Drug Saf 1992;1:19-23.
42. Peterson S, Rayner M. Coronary heart disease statistics. London: British Heart Foundation, 2002.
43. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
44. Layton D, Heeley E, Hughes K, Shakir S. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology 2003; Advance Access publication: June 30, 2003, DOI: 10.1093/rheumatology/keg379.
45. Martindale 32nd edition. London: Pharmaceutical Press, 2002.
46. Layton D, Hughes K, Harris S, Shakir SA. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology 2003; Advance Access publication: June 16, 2003, DOI: 10.1093/rheumatology/keg376.
47. Raskin JB. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999;106:3S-12S.
48. Lanes S, Garcia Rodriguez LA, Hwang E. Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin. Pharmacoepidemiol Drug Saf 2002;9:113-17.
49. Layton D, Riley J, Wilton LW, Shakir S. Safety profile of rofecoxib as used in general practice in England: results of a Prescription-Event Monitoring study. Br J Clin Pharmacol 2002;55:166-74.
50. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002;47:349-55.
51. The physicians' health study: aspirin for the primary prevention of myocardial infarction. N Engl J Med 1988;318:924-6.
52. Ray W, Stein C, Daugherty J, Hall K, Arbogast P, Griffin M. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071.